CEO Saumya Sutaria Sells $27.6M in Tenet Shares — Double the Noticed Amount
THC sits 76% above its 52-week low of $157.58.
Summary
Tenet Healthcare CEO Saumya Sutaria sold $27.6 million in stock, double the amount he had noticed just two days prior, adding to a broader insider selling trend.
Key Events · Ownership and Investor Activity · THC
-
CEO Sells $27.6M in Stock
Saumya Sutaria sold 100,000 shares at $273.34-$278.90 on Aug 24-25, totaling $27,636,334.52.
-
Sale Double the Noticed Amount
The Form 144 filed Aug 24 noticed only 50,000 shares (~$13.9M); actual sale was 100,000 shares — a material divergence.
-
Insider Distribution Trend
Seven insiders have sold $10.86M in open-market sales over the last 90 days, with no open-market purchases.
-
Near 52-Week High
Sale executed at $273-$279, near the 52-week high of $283.05, following strong Q2 earnings and a $2B buyback authorization.
Analysis · THC · Industrial Applications And Services
CEO Saumya Sutaria sold 100,000 shares for $27.6 million on August 24-25, at prices between $273.34 and $278.90. This is double the 50,000 shares (~$13.9M) he had noticed in a Form 144 filed just two days earlier. The sale comes near the stock's 52-week high and follows a pattern of insider distribution — seven insiders have sold over $10.8 million in the last 90 days. While the company recently raised guidance and authorized a $2 billion buyback, the CEO's larger-than-noticed sale is a notable negative signal for a key insider.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, THC was trading at $277.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $21.9B. The 52-week trading range was $157.58 to $283.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.